Cerevel Therapeutics Holdings, Inc.·4

Dec 19, 4:15 PM ET

Sanchez Ramiro 4

4 · Cerevel Therapeutics Holdings, Inc. · Filed Dec 19, 2023

Insider Transaction Report

Form 4
Period: 2023-12-15
Sanchez Ramiro
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2023-12-15$41.39/sh7,500$310,3930 total
  • Exercise/Conversion

    Common Stock

    2023-12-15$9.88/sh+7,500$74,1007,500 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-12-157,500123,390 total
    Exercise: $9.88Exp: 2030-10-28Common Stock (7,500 underlying)
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.385 to $41.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]50% of the shares subject to this option vested and became exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4